Recursion Pharmaceuticals is a biotechnology company that combines high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets.
Recursion Pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics.
Recursion Pharmaceuticals was founded in Nov 5, 2013 by Blake Borgeson, Chris Gibson & Dean Li and is based in Salt Lake City, Utah, United States.
Recursion Pharmaceuticals offers drug discovery and treatments using artificial intelligence, automation, bioinformatics, and experimental biology.
Recursion Pharmaceuticals's platform has resulted in the massive parallelization of drug discovery. They have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases.
Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives.
Recursion Pharmaceuticals is backed by AME Cloud Ventures, CRV, Menlo Ventures, Logo of Felicis Ventures, Scottish Mortgage Investment Trust and others. The company raised $121M in its latest funding of a "Series C" round on Jul 15, 2019. This brings Recursion's total funding to $226.4M to-date.